Pathophysiology
Inhaled or aspirated pathogens overcome mucociliary and alveolar macrophage defences to multiply in the alveoli. Neutrophil influx, exudate and fibrin fill alveoli, producing consolidation and impaired gas exchange. Typical (S. pneumoniae, H. influenzae, Moraxella) cause lobar disease with rusty sputum; atypicals (Mycoplasma, Chlamydia pneumoniae, Legionella) produce interstitial patterns with lower fever and dry cough.
Sources: ATS/IDSA CAP Guideline (AJRCCM 2019;200:e45); NICE NG138 Pneumonia
Clinical presentation
Acute cough, purulent sputum, fever/chills, dyspnoea, pleuritic chest pain. Exam: tachypnoea, bronchial breath sounds, dullness to percussion, egophony, increased tactile fremitus. Elderly may present only with confusion or falls. Red flags: hypotension, SpO2 <90%, altered mental status.
Sources: ATS/IDSA CAP Guideline (AJRCCM 2019;200:e45); NICE NG138 Pneumonia
Diagnosis
Chest X-ray shows infiltrate (lobar, patchy, or interstitial). Labs: WBC with left shift, elevated CRP/procalcitonin. Blood cultures and sputum Gram stain/culture for hospitalised patients. Urinary antigens for pneumococcus and Legionella in severe CAP. Respiratory viral PCR during viral seasons. CURB-65 (Confusion, Urea >7 mmol/L, RR ≥30, BP <90/60, age ≥65) scores site of care: 0-1 outpatient, 2 admit, ≥3 ICU consideration.
Sources: ATS/IDSA CAP Guideline (AJRCCM 2019;200:e45); NICE NG138 Pneumonia
Empiric antibiotic therapy
Outpatient healthy adult: amoxicillin 1 g TID or doxycycline. Comorbidities/recent antibiotics: amoxicillin-clavulanate + macrolide or doxycycline, or respiratory fluoroquinolone (levofloxacin, moxifloxacin). Inpatient non-ICU: ceftriaxone + macrolide OR respiratory fluoroquinolone. ICU: beta-lactam + macrolide (or fluoroquinolone). Cover MRSA/Pseudomonas when risk factors present. Total duration 5 days if afebrile ≥48 h and clinically stable.
Sources: ATS/IDSA CAP Guideline (AJRCCM 2019;200:e45); NICE NG138 Pneumonia
Prevention & complications
Vaccinate high-risk patients (age ≥65, chronic disease, immunocompromised) with PCV20 or PCV15 + PPSV23, annual influenza and COVID-19 vaccines. Complications: parapneumonic effusion, empyema, lung abscess, sepsis, ARDS. Follow-up CXR at 6 weeks in smokers >50 y to exclude underlying malignancy.
Sources: ATS/IDSA CAP Guideline (AJRCCM 2019;200:e45); NICE NG138 Pneumonia







